vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and FIRST INTERSTATE BANCSYSTEM INC (FIBK). Click either name above to swap in a different company.
FIRST INTERSTATE BANCSYSTEM INC is the larger business by last-quarter revenue ($313.0M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). FIRST INTERSTATE BANCSYSTEM INC runs the higher net margin — 34.8% vs -0.7%, a 35.5% gap on every dollar of revenue. On growth, FIRST INTERSTATE BANCSYSTEM INC posted the faster year-over-year revenue change (19.8% vs 0.7%). Over the past eight quarters, FIRST INTERSTATE BANCSYSTEM INC's revenue compounded faster (13.7% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
First Interstate BancSystem, Inc. is a financial holding company headquartered in Billings, Montana. It is the parent company of First Interstate Bank, a community bank with locations throughout 14 states within the Western and Midwestern United States. It is the largest bank based in Montana, as measured by total assets.
AVNS vs FIBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $313.0M |
| Net Profit | $-1.3M | $108.8M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 44.5% |
| Net Margin | -0.7% | 34.8% |
| Revenue YoY | 0.7% | 19.8% |
| Net Profit YoY | 99.7% | 108.8% |
| EPS (diluted) | $-0.02 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $313.0M | ||
| Q3 25 | $177.8M | $250.5M | ||
| Q2 25 | $175.0M | $248.3M | ||
| Q1 25 | $167.5M | $247.0M | ||
| Q4 24 | $179.6M | $261.3M | ||
| Q3 24 | $170.4M | $251.9M | ||
| Q2 24 | $171.7M | $244.3M | ||
| Q1 24 | $166.1M | $242.2M |
| Q4 25 | $-1.3M | $108.8M | ||
| Q3 25 | $-1.4M | $71.4M | ||
| Q2 25 | $-76.8M | $71.7M | ||
| Q1 25 | $6.6M | $50.2M | ||
| Q4 24 | $-397.3M | $52.1M | ||
| Q3 24 | $4.3M | $55.5M | ||
| Q2 24 | $1.8M | $60.0M | ||
| Q1 24 | $-900.0K | $58.4M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 44.5% | ||
| Q3 25 | 0.1% | 37.0% | ||
| Q2 25 | -42.6% | 37.7% | ||
| Q1 25 | 6.1% | 26.9% | ||
| Q4 24 | -233.0% | 25.5% | ||
| Q3 24 | 7.0% | 28.9% | ||
| Q2 24 | 3.7% | 32.1% | ||
| Q1 24 | 2.4% | 31.7% |
| Q4 25 | -0.7% | 34.8% | ||
| Q3 25 | -0.8% | 28.5% | ||
| Q2 25 | -43.9% | 28.9% | ||
| Q1 25 | 3.9% | 20.3% | ||
| Q4 24 | -221.2% | 19.9% | ||
| Q3 24 | 2.5% | 22.0% | ||
| Q2 24 | 1.0% | 24.6% | ||
| Q1 24 | -0.5% | 24.1% |
| Q4 25 | $-0.02 | $1.07 | ||
| Q3 25 | $-0.03 | $0.69 | ||
| Q2 25 | $-1.66 | $0.69 | ||
| Q1 25 | $0.14 | $0.49 | ||
| Q4 24 | $-8.64 | $0.50 | ||
| Q3 24 | $0.09 | $0.54 | ||
| Q2 24 | $0.04 | $0.58 | ||
| Q1 24 | $-0.02 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | $146.3M |
| Stockholders' EquityBook value | $778.2M | $3.4B |
| Total Assets | $1.1B | $26.6B |
| Debt / EquityLower = less leverage | 0.12× | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | — | ||
| Q3 24 | $89.0M | — | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | $146.3M | ||
| Q3 25 | $93.4M | $146.2M | ||
| Q2 25 | $95.7M | $252.0M | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | $132.2M | ||
| Q3 24 | $152.6M | $137.3M | ||
| Q2 24 | $164.9M | $383.4M | ||
| Q1 24 | $167.2M | $370.8M |
| Q4 25 | $778.2M | $3.4B | ||
| Q3 25 | $778.0M | $3.4B | ||
| Q2 25 | $776.3M | $3.4B | ||
| Q1 25 | $839.4M | $3.4B | ||
| Q4 24 | $828.5M | $3.3B | ||
| Q3 24 | $1.2B | $3.4B | ||
| Q2 24 | $1.2B | $3.2B | ||
| Q1 24 | $1.2B | $3.2B |
| Q4 25 | $1.1B | $26.6B | ||
| Q3 25 | $1.1B | $27.3B | ||
| Q2 25 | $1.0B | $27.6B | ||
| Q1 25 | $1.1B | $28.3B | ||
| Q4 24 | $1.2B | $29.1B | ||
| Q3 24 | $1.7B | $29.6B | ||
| Q2 24 | $1.7B | $30.3B | ||
| Q1 24 | $1.7B | $30.1B |
| Q4 25 | 0.12× | 0.04× | ||
| Q3 25 | 0.12× | 0.04× | ||
| Q2 25 | 0.12× | 0.07× | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | 0.04× | ||
| Q3 24 | 0.12× | 0.04× | ||
| Q2 24 | 0.13× | 0.12× | ||
| Q1 24 | 0.14× | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $305.6M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $305.6M | ||
| Q3 25 | $14.0M | $91.7M | ||
| Q2 25 | $6.8M | $68.1M | ||
| Q1 25 | $25.7M | $78.5M | ||
| Q4 24 | $57.9M | $355.0M | ||
| Q3 24 | $23.0M | $89.9M | ||
| Q2 24 | $27.8M | $82.3M | ||
| Q1 24 | $-8.0M | $87.6M |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | — | ||
| Q3 24 | $20.0M | — | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | — | ||
| Q3 24 | 11.7% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | 2.81× | ||
| Q3 25 | — | 1.28× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | 3.89× | 1.56× | ||
| Q4 24 | — | 6.81× | ||
| Q3 24 | 5.35× | 1.62× | ||
| Q2 24 | 15.44× | 1.37× | ||
| Q1 24 | — | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FIBK
Segment breakdown not available.
